Braeburn, Camurus extend partnership, license agreement
The two companies began their collaboration in 2014.
"This new product candidate has the potential to expand Braeburn's ability to offer relief across the continuum of postoperative pain management, including addressing the often co-occurring symptoms of nausea and vomiting," Braeburn President and CEO Behshad Sheldon said.
CAM2058 will be the first product that the two companies will develop under the extended license agreement. CAM2058 is an extended-release medication combining buprenorphine and granisetron that is administered as an injection.
"We believe that CAM2058 has the potential to improve the wellbeing of patients post-surgery and reduce the need for other medications including oral opioid painkillers, which are taken home and self-administered by the patient,” Camurus President and CEO Fredrik Tiberg said. “The partnership with Braeburn Pharmaceuticals is a strong platform for the further global development of this new asset. CAM2058 combines these two treatment modalities in a single, small volume, sustained release injection which is made possible by using our FluidCrystal technology."